Live Quote · NASDAQNNNNHealthcare· Medical - Instruments & Supplies

Anbio Biotechnology Class A Ordinary Shares

$12.70 2.88%(+$0.35)
TickerSpark Score
67/100
Solid
40
Valuation
100
Profitability
80
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNNN research report →

52-Week Range5% of range
Low
$10.50
Current
$12.70
High
$55.65
Company Overviewwww.anbio.com

About the company

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B).

CEO
Michael Lau
IPO
2025
Employees
27
HQ
Frankfurt am Main, DE

Price Chart

-64.92% · this period
$52.10$32.20$12.29Jul 02Dec 31Jul 02
Valuation
Market Cap
$557.42M
P/E
77.58
P/S
57.20
P/B
18.49
EV/EBITDA
84.86
Div Yield
0.00%
Profitability
Gross Margin
87.06%
Op Margin
66.47%
Net Margin
73.75%
ROE
23.00%
ROIC
21.48%
Growth & Income
Revenue
$8.65M · 5.64%
Net Income
$6.40M · 169.86%
EPS
$0.16 · 185.71%
Op Income
$5.77M
FCF YoY
-423.93%
Performance & Tape
52W High
$55.65
52W Low
$10.50
50D MA
$23.95
200D MA
$26.75
Beta
5.10
Avg Volume
33.52K

Get TickerSpark's AI analysis on NNNN

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Mar 18, 26ZHANG MICHAEL W.Cother0
Mar 18, 26HSU DAVID Hother0
Mar 18, 26Song Sukiother0
Mar 18, 26Hartzler Nancyother0
Mar 18, 26LAU MICHAELother0
Mar 18, 26TIAN CHRISother0
Mar 18, 26XU CANYother0
Coverage · NNNN

Our NNNN coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on NNNN yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate NNNN report →
Internal Compare

Similar companies

Peers in the same neighborhood.